Lawrence Wayne Dillard

This inventor holds 64 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 18 EPO patents, primarily in ROR-Gamma Inhibitors (CPC class C07D). Top assignees: Vitae Pharmaceuticals, Inc., Schering Corporation, Pharmacopeia Inc.. Active years: 1996-2025.

USPTO Granted Patents = 64 (Patent Applications = 15)

% Patents Active = 71.9

CIPO Patents = 5 (Patent Applications = 8)

EPO Patents = 18 (Patent Applications = 18)

Average Co-Inventor Count = 9.3

ph-index = 13

Forward Citations = 886(Granted Patents)

Forward Citations (Not Self Cited) = 769(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Hopewell, NJ (US) (1997 - 2004)
Plainsboro, NJ (US) (1996 - 2005)
Skillman, NJ (US) (2006 - 2014)
Yardley, PA (US) (2008 - 2022)

Company Filing History:

38 out of 85

Vitae Pharmaceuticals, Inc.

Pharmacopeia Drug Discovery, Inc.

patents

5. 6 out of 196

Cold Spring Harbor Laboratory

Boehringer Ingelheim International Gmbh

patents

8. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

9. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

ROR-Gamma

Beta-Secretase

Aspartic Protease

Dihydropyrrolopyridine

Inhibitors

Modulators

Piperidine

Thiazolopyrrolidine

Isoindoline

Cyclin Dependent Kinase

Benzimidazole

Substituted Indoles

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312359 - Inhibitors of the menin-MLL interaction (2025-05-27),

2. 11535614 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2022-12-27),

3. 11479557 - Inhibitors of the menin-MLL interaction (2022-10-25),

4. 11008340 - Modulators of ROR-gamma (2021-05-18),

5. 11001583 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2021-05-11),

6. 10829481 - Benzimidazole derivatives as modulators of ROR-gamma (2020-11-10),

7. 10829448 - Substituted benzoimidazoles as modulators of ROR-γ (2020-11-10),

8. 10807980 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2020-10-20),

9. 10683302 - Inhibitors of the menin-MLL interaction (2020-06-16),

10. 10399976 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2019-09-03),

11. 10336717 - Inhibitors of beta-secretase (2019-07-02),

12. 10301261 - Substituted indoles as modulators of ROR-gamma (2019-05-28),

13. 10087184 - Dihydropyrrolopyridine inhibitors of RORγ (2018-10-02),

14. 10047085 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2018-08-14),

15. 9949975 - Inhibitors of beta-secretase (2018-04-24),

Title: Lawrence Wayne Dillard: Pioneering Inventor from Yardley, PA

Introduction: Lawrence Wayne Dillard is a distinguished inventor hailing from Yardley, Pennsylvania. With a passion for innovation and a keen eye for problem-solving, Dillard has made significant contributions to the field of technology through his groundbreaking inventions.

Latest Patents: Dillard's latest patents showcase his expertise in developing cutting-edge solutions for various industries, ranging from healthcare to consumer electronics. His innovative approach has led to the creation of patents that are revolutionizing their respective fields.

Career Highlights: Throughout his illustrious career, Lawrence Wayne Dillard has been recognized for his exceptional creativity and ingenuity. His inventions have not only garnered critical acclaim but have also made a tangible impact on society, improving the lives of many.

Collaborations: Dillard has collaborated with leading industry experts, researchers, and engineers to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects, leading to the development of groundbreaking technologies.

Conclusion: Lawrence Wayne Dillard's relentless pursuit of innovation and his unwavering dedication to creating transformative solutions have solidified his reputation as a pioneering inventor in Yardley, PA. His contributions to the world of technology continue to inspire future generations of inventors and innovators.